BFC Planning’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VKTX
BFC Planning's VKTX Position: Q3 2026 in Review
BFC Planning increased its Viking Therapeutics (VKTX) stake by 59% in Q3 2026, buying an estimated $1.73K and bringing the position to 135 shares worth $4.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2737.
BFC Planning first reported a position in VKTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $10.6K in Q3 2024. 330 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.
- BFC Planning held 135 shares of Viking Therapeutics worth $4.4K as of Q3 2026.
- BFC Planning bought 50 Viking Therapeutics shares in Q3 2026, an estimated $1.73K.
- Viking Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2737 holding.
- BFC Planning first reported a position in Viking Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Viking Therapeutics position peaked at $10.6K in Q3 2024.
- 330 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.